Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed-cisplatin chemoradiation versus etoposide-cisplatin chemoradiation in unresectable stage III nonsquamous NSCLC
2008-001170-32Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemetrexed, cisplatin and etoposide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: overall survival. Started May 2008; status: completed.
02
Drugs
pemetrexedcisplatinetoposide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-001170-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001170-32.